JP2019512207A5 - - Google Patents

Download PDF

Info

Publication number
JP2019512207A5
JP2019512207A5 JP2018536458A JP2018536458A JP2019512207A5 JP 2019512207 A5 JP2019512207 A5 JP 2019512207A5 JP 2018536458 A JP2018536458 A JP 2018536458A JP 2018536458 A JP2018536458 A JP 2018536458A JP 2019512207 A5 JP2019512207 A5 JP 2019512207A5
Authority
JP
Japan
Prior art keywords
amino acid
acid sequence
variable region
chain variable
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018536458A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019512207A (ja
JP7022067B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/013511 external-priority patent/WO2017124001A2/en
Publication of JP2019512207A publication Critical patent/JP2019512207A/ja
Publication of JP2019512207A5 publication Critical patent/JP2019512207A5/ja
Application granted granted Critical
Publication of JP7022067B2 publication Critical patent/JP7022067B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018536458A 2016-01-14 2017-01-13 Ｆｏｘｐ３由来のペプチドに特異的なｔ細胞受容体様抗体 Expired - Fee Related JP7022067B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662278815P 2016-01-14 2016-01-14
US62/278,815 2016-01-14
PCT/US2017/013511 WO2017124001A2 (en) 2016-01-14 2017-01-13 T cell receptor-like antibodies specific for foxp3-derived peptides

Publications (3)

Publication Number Publication Date
JP2019512207A JP2019512207A (ja) 2019-05-16
JP2019512207A5 true JP2019512207A5 (enExample) 2020-02-20
JP7022067B2 JP7022067B2 (ja) 2022-02-17

Family

ID=59311684

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018536458A Expired - Fee Related JP7022067B2 (ja) 2016-01-14 2017-01-13 Ｆｏｘｐ３由来のペプチドに特異的なｔ細胞受容体様抗体

Country Status (5)

Country Link
US (1) US11505599B2 (enExample)
EP (1) EP3402518A4 (enExample)
JP (1) JP7022067B2 (enExample)
CN (1) CN109069627A (enExample)
WO (1) WO2017124001A2 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6974311B2 (ja) * 2015-06-23 2021-12-01 メモリアル スローン ケタリング キャンサー センター 新規ｐｄ−１免疫調節剤
MX2018004721A (es) 2015-10-23 2018-07-06 Eureka Therapeutics Inc Construcciones quimericas anticuerpo/receptor de celulas t y usos de las mismas.
WO2018200582A1 (en) 2017-04-26 2018-11-01 Eureka Therapeutics, Inc. Chimeric antibody/t-cell receptor constructs and uses thereof
MX2020001879A (es) * 2017-08-18 2020-07-29 Gritstone Oncology Inc Proteínas de fijación al antígeno que se dirigen a antígenos compartidos.
CN112041432A (zh) * 2018-02-15 2020-12-04 纪念斯隆-凯特林癌症中心 Foxp3靶向剂组合物以及用于过继细胞疗法的使用方法
CN113603783B (zh) * 2018-12-21 2022-07-12 浙江时迈药业有限公司 蛋白酶可切割的双特异性抗体及其用途
WO2022082030A2 (en) 2020-10-15 2022-04-21 Gritstone Bio, Inc. Antigen-binding proteins and related methods of use
WO2022155503A1 (en) 2021-01-14 2022-07-21 Gritstone Bio, Inc. Multi-specific antibodies and methods of use
WO2022165419A1 (en) 2021-02-01 2022-08-04 Kyverna Therapeutics, Inc. Methods for increasing t-cell function
US20230056336A1 (en) * 2021-04-15 2023-02-23 Kyverna Therapeutics, Inc. Methods and compositions for treating disease using targeted foxp3+cd4+ t cells and cellular suicide agents
WO2024100170A1 (en) 2022-11-11 2024-05-16 F. Hoffmann-La Roche Ag Antibodies binding to hla-a*02/foxp3
US20260226173A1 (en) * 2023-02-06 2026-08-06 Memorial Sloan-Kettering Cancer Center Compositions including anti-wt-1 antibodies & antigen binding fragments and uses thereof
WO2025145063A1 (en) * 2023-12-29 2025-07-03 Eureka Therapeutics, Inc. Constructs targeting msln peptide/mhc complexes and uses thereof
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
CN122187960B (zh) * 2026-05-15 2026-08-07 四川大学华西医院 一种针对呼吸道合胞病毒的强效中和抗体rsv-34及其应用

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1975A (en) 1841-02-12 Manner of constructing corn-shellers
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
JPS6412935A (en) 1987-07-02 1989-01-17 Mitsubishi Electric Corp Constant-speed travel device for vehicle
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
EP0401384B1 (en) 1988-12-22 1996-03-13 Kirin-Amgen, Inc. Chemically modified granulocyte colony stimulating factor
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
AU4116793A (en) 1992-04-24 1993-11-29 Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
EP0983303B1 (en) 1997-05-21 2006-03-08 Biovation Limited Method for the production of non-immunogenic proteins
HUP0104865A3 (en) 1999-01-15 2004-07-28 Genentech Inc Polypeptide variants with altered effector function
US6436703B1 (en) 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
US20030059427A1 (en) * 2000-04-28 2003-03-27 Force Walker R. Isolation and characterization of highly active anti-CD40 antibody
CA2658221C (en) * 2001-04-27 2012-11-27 Kyowa Kirin Co., Ltd. Anti-cd40 monoclonal antibody
US20100003253A1 (en) * 2002-11-08 2010-01-07 Ablynx N.V. Single domain antibodies directed against epidermal growth factor receptor and uses therefor
NZ540194A (en) 2002-11-08 2008-07-31 Ablynx Nv Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
US9320792B2 (en) 2002-11-08 2016-04-26 Ablynx N.V. Pulmonary administration of immunoglobulin single variable domains and constructs thereof
PL2314621T3 (pl) 2004-05-27 2014-08-29 Crucell Holland Bv Cząsteczki wiążące zdolne do neutralizowania wirusa wścieklizny i ich zastosowania
JP4829609B2 (ja) 2004-12-22 2011-12-07 独立行政法人科学技術振興機構 ヒト抗体酵素およびその生産方法
EP1937814A4 (en) 2005-09-01 2010-05-05 Ca Nat Research Council ANTIAPOPTOTIC PROTEIN ANTIBODY
WO2008066784A2 (en) * 2006-11-27 2008-06-05 Ludwig Institute For Cancer Research Expression of foxp3 by cancer cells
TWI441648B (zh) * 2007-01-03 2014-06-21 Oncotherapy Science Inc Ｆｏｘｐ３胜肽疫苗
WO2009003489A1 (en) * 2007-07-02 2009-01-08 Natimmune A/S CaOU-1 EPITOPE BINDING POLYPEPTIDES
EP2020419A1 (en) * 2007-07-31 2009-02-04 Bayer Schering Pharma Aktiengesellschaft Anti ephB4 antibody fragments
EP3524619A1 (en) 2007-12-06 2019-08-14 Dana-Farber Cancer Institute, Inc. Antibodies against influenza virus and methods of use thereof
EP2246426A4 (en) * 2008-01-29 2011-08-10 Inst Antibodies Co Ltd COMPOSITION FOR THE NEUTRALIZATION OF BOTULINUS TOXIN TYPE-A AND HUMAN ANTIBODIES AGAINST BOTULINUS TOXIN TYPE-A
BRPI0911501A2 (pt) * 2008-04-29 2015-07-28 Monsanto Technology Llc Genes e usos para melhoramento de plantas.
US20120005773A1 (en) * 2008-10-01 2012-01-05 Aasen Eric D Transgenic plants with enhanced agronomic traits
US9221902B2 (en) * 2008-11-07 2015-12-29 Fabrus, Inc. Combinatorial antibody libraries and uses thereof
WO2010099083A1 (en) * 2009-02-27 2010-09-02 Monsanto Technology Llc Isolated novel nucleic acid and protein molecules from soybeans and methods of using those molecules
JP6012473B2 (ja) 2010-01-11 2016-10-25 アレクシオン ファーマシューティカルズ， インコーポレイテッド 抗ｃｄ２００抗体を用いたヒトの処置における免疫調節効果のバイオマーカー
PH12013501201A1 (en) * 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
SG191977A1 (en) * 2011-02-01 2013-08-30 Genmab As Human antibodies and antibody-drug conjugates against cd74
WO2015070061A1 (en) * 2013-11-07 2015-05-14 Memorial Sloan-Kettering Cancer Center Anti-wt1/hla bi-specific antibody
US20130102031A1 (en) * 2011-10-25 2013-04-25 Anaptysbio, Inc. Use of somatic hypermutation to create insertion and deletion mutations in vitro
US9175082B2 (en) * 2012-05-31 2015-11-03 Sorrento Therapeutics, Inc. Antigen binding proteins that bind PD-L1
WO2014036562A2 (en) * 2012-08-31 2014-03-06 University Of Virginia Patent Foundation Target peptides for immunotherapy and diagnostics
US10273301B2 (en) 2013-12-24 2019-04-30 Janssen Pharmaceutica Nv Anti-vista antibodies and fragments
GB201410520D0 (en) 2014-06-12 2014-07-30 Univ London Queen Mary Antibody

Similar Documents

Publication Publication Date Title
US10781256B2 (en) Anti SIRP-α antibodies and bi-specific macrophage enhancing antibodies
CN107405397B (zh) 抗tim-3抗体
JP2020501531A5 (enExample)
CN110891650A (zh) 制导和导航控制蛋白及其制造和使用方法
KR20180114218A (ko) 항-lag-3 항체
CN117285642A (zh) 制导和导航控制蛋白及其制备和使用方法
JP2021511818A (ja) Ｖｉｓｔａ抗原結合性分子
CN108337890A (zh) 新型pd-1免疫调节剂
JP2017535257A5 (enExample)
CN107428832A (zh) 抗pd‑l1抗体
JP2013506428A5 (enExample)
JP2018500014A5 (enExample)
CN110831973A (zh) 多特异性抗体及其制备和使用方法
CN110799540A (zh) 多特异性抗体及其制备和使用方法
JP7418326B2 (ja) 二重特異性抗体並びにその製造方法及び使用方法
EP3664843A1 (en) Cd96-binding agents as immunomodulators
CN112292399A (zh) 抗cd27抗体及其用途
WO2021121373A1 (zh) 抗人程序死亡因子-1单克隆抗体
KR20210027254A (ko) Tim-3에 대한 항체 및 그의 용도
EP4168450A2 (en) Cd38 antibodies for the treatment of human diseases
JP2016529213A5 (enExample)
Sandeep et al. Engineered polyspecific antibodies: A new frontier in the field of immunotherapeutics
AU2018370120A1 (en) Methods for selective expansion of d3 yd T-cell populations and compositions thereof
JP2020533002A5 (enExample)
TW202328196A (zh) 使用vista抗原結合分子的癌症之治療及預防